Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden

الملخص EN

Background.

Immunotherapy offers a novel approach for the treatment of cutaneous melanoma, but the clinical efficiency varies for individual patients.

In consideration of the high cost and adverse effects of immunotherapy, it is essential to explore the predictive biomarkers of outcomes.

Recently, the tumor mutation burden (TMB) has been proposed as a predictive prognosticator of the immune response.

Method.

RNA-seq and somatic mutation datasets of 472 cutaneous melanoma patients were downloaded from The Cancer Genome Atlas (TCGA) database to analyze mutation type and TMB.

Differently expressed genes (DEGs) were identified for functional analysis.

TMB-related signatures were identified via LASSO and multivariate Cox regression analysis.

The association between mutants of signatures and immune cells was evaluated from the TIMER database.

Furthermore, the Wilcox test was applied to assess the difference in immune infiltration calculated by the CIBERSORT algorithm in risk groupings.

Results.

C>T substitutions and TTN were the most common SNV and mutated gene, respectively.

Patients with low TMB presented poor prognosis.

DEGs were mainly implicated in skin development, cell cycle, DNA replication, and immune-associated crosstalk pathways.

Furthermore, a prognostic model consisting of eight TMB-related genes was developed, which was found to be an independent risk factor for treatment outcome.

The mutational status of eight TMB-related genes was associated with a low level of immune infiltration.

In addition, the immune infiltrates of CD4+ and CD8+ T cells, NK cells, and M1 macrophages were higher in the low-risk group, while those of M0 and M2 macrophages were higher in the high-risk group.

Conclusion.

Our study demonstrated that a higher TMB was associated with favorable survival outcome in cutaneous melanoma.

Moreover, a close association between prognostic model and immune infiltration was identified, providing a new potential target for immunotherapy.